Kyverna Therapeutics (KYTX) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kyverna Therapeutics (KYTX) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 39.9% versus a loss of 67.3%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $245.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | LXEO |
|---|---|---|
| Share price | $4.26 | $2.96 |
| Market cap | $269.33M | $245.05M |
| 1-day change | -2.52% | +0.34% |
| YTD return | -54.68% | -70.19% |
| 1-year return | -39.92% | -67.33% |
| EPS (TTM) | $-2.75 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-161.31M | $-100.00M |
| 52-week high | $13.67 | $10.99 |
| 52-week low | $4.18 | $2.55 |
| Distance from 52-week high | -68.84% | -73.07% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +613.62% | +748.31% |
| Average volume | 867.28K | 1.98M |
| Shares outstanding | 63.22M | 82.79M |
| Employees | 172 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYTX has outperformed LXEO by 27.4 percentage points over the past year.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
KYTX vs LXEO FAQ
Which is bigger, Kyverna Therapeutics or Lexeo Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $245.05M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, KYTX or LXEO?
KYTX returned -39.92% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.